RELEASE 300 MG/ML, SOLUTION FOR INJECTION

국가: 아일랜드

언어: 영어

출처: HPRA (Health Products Regulatory Authority)

유효 성분:

PENTOBARBITAL SODIUM

제공처:

WDT - Wirtschaftsgenossenschaft deutscher Tierarzte eG

ATC 코드:

QN51AA01

INN (International Name):

PENTOBARBITAL SODIUM

복용량:

300 Mg/Ml

약제 형태:

Solution for Injection

처방전 유형:

VPO-Vet.Practitioner Only

치료 그룹:

Avian, Bovine, Canine, Equine Non Food, Feline, Fowl - Chicken, Guinea Pigs, Hamsters, Mink, Non Food Animals, Porcine, Rabbits,

치료 영역:

Pentobarbital

치료 징후:

Neurological Preparations

승인 상태:

Authorised

승인 날짜:

2008-10-24

제품 특성 요약

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Release 300 mg/ml, solution for injection
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains
Active substance:
pentobarbital sodium
300 mg
Excipients:
patent blue V (E 131)
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Solution for injection
A clear, blue solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Horses, ponies, cattle, swine, dogs, cats, minks, polecats, hares, rabbits, guinea pigs, hamsters, rats, mice, chicken,
pigeons, birds, snakes, tortoises, lizards, frogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For euthanasia in animals.
4.3 CONTRAINDICATIONS
Do not use in animals intended for human or animal consumption.
Do not use for anaesthetic purposes.
Do not use for intracoelmic injection in chelonia as the time to death may be unnecessarily prolonged compared with
intravenous administration.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 24/10/2016_
_CRN 7023396_
_page number: 1_
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Carcases of animals euthanised with this product should be disposed of in accordance with national legislation.
Carcases of animals euthanised with this product should not be fed to other animals due to the risk of secondary
intoxication.
The intraperitoneal route of administration may cause a prolonged onset of action with an increased risk of adverse
effects noted in 4.6. Prior sedation is advisable.
The intrapulmonary route of administration may cause a prolonged onset of action with an increased risk of adverse
effects noted in 4.6 and should be reserved for cases where other routes of administration are not possible. Prior
s